Faron Announces First Patient Dosed in BLAZE Investigator-Initiated Trial

First clinical evaluation of bexmarilimab plus nivolumab in patients with anti-PD-1-resistant solid tumors TURKU, FI / ACCESS Newswire / October 1, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN) , a global, clinical-stage biopharmaceutical …